according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Tafluprost Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Not applicable

Use of the Sub- : Pharmaceutical

stance/Mixture

initialo

on use

1.3 Details of the supplier of the safety data sheet

Company : MSD

Piercetown

A86 HD21 Dunboyne, Ireland

Telephone : 908-740-4000

E-mail address of person

Recommended restrictions

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.1 28.09.2024 564736-00020 Date of first issue: 15.03.2016

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Tafluprost	209860-87-7	Acute Tox. 4; H302	>= 0.0002 - <
		Eye Irrit. 2; H319	0.0025
		Repr. 1B; H360D	
		STOT SE 1; H370	
		(Lungs, Cardio-	
		vascular system)	
		STOT RE 1; H372	
		(Lungs, Cardio-	
		vascular system)	
		Aquatic Chronic 4;	
		H413	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

Protection of first-aiders : No special precautions are necessary for first aid responders.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

None known.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

5.3 Advice for firefighters

Special protective equipment :

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary. Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Handle in accordance with good industrial hygiene and safety

practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Gases

7.3 Specific end use(s)

Specific use(s) : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Tafluprost	209860-87- 7	TWA	0.002 μg/m3 (OEB 5)	Internal
	Further information: Skin, Eye			
		Wipe limit	0.02 μg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerine	Workers	Inhalation	Long-term local ef- fects	56 mg/m3
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local ef- fects	33 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Glycerine	Fresh water	0.885 mg/l
	Marine water	0.0885 mg/l
	Intermittent use/release	8.85 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3.3 mg/kg dry
		weight (d.w.)
	Marine sediment	0.33 mg/kg dry
		weight (d.w.)
	Soil	0.141 mg/kg dry
		weight (d.w.)

8.2 Exposure controls

Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

Wear a faceshield or other full face protection if there is a

potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387

Filter type : Organic vapour type (A)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : Aqueous solution

Colour : clear

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Tafluprost:

Acute oral toxicity : LD50 (Rat): 665 mg/kg

LD50 (Rat): > 100 mg/kg

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of :

administration)

(Dog): 3 mg/kg

Application Route: Intravenous

Target Organs: Cardio-vascular system

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Tafluprost:

Species : Monkey

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Tafluprost:

Test Type : Maximisation Test

Exposure routes : Dermal

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

Species : Guinea pig

Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

Tafluprost:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Tafluprost:

Species : Rat

Application Route : Subcutaneous Exposure time : 24 Months Result : negative

Species : Mouse

Application Route : Subcutaneous Exposure time : 18 Months Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Tafluprost:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Intravenous injection

Fertility: NOAEL: 100 µg/kg Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

Developmental Toxicity: LOAEL: 10 µg/kg

Result: Malformations were observed., Reduced foetal weight

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection Developmental Toxicity: NOAEL: 3 µg/kg

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous injection Developmental Toxicity: LOAEL: 0.03 µg/kg Result: Malformations were observed.

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous injection Developmental Toxicity: NOAEL: 0.01 µg/kg

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection Developmental Toxicity: LOAEL: 1 µg/kg

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection Developmental Toxicity: NOAEL: 0.3 µg/kg

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

Components:

Tafluprost:

Target Organs : Lungs, Cardio-vascular system Assessment : Causes damage to organs.

STOT - repeated exposure

Not classified based on available information.

Components:

Tafluprost:

Target Organs : Lungs, Cardio-vascular system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

Repeated dose toxicity

Components:

Tafluprost:

Species : Rat

LOAEL : 0.01 mg/kg
Application Route : Intravenous
Exposure time : 6 Months

Target Organs : Cardio-vascular system, Blood, Bone marrow, Kidney, Liver,

spleen

Species : Dog

NOAEL : 0.0001 mg/kg
LOAEL : 0.001 mg/kg
Application Route : Intravenous
Exposure time : 39 Weeks

Target Organs : Cardio-vascular system, Eye

Symptoms : Dilatation of the pupil

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Tafluprost:

Eye contact : Symptoms: dryness of the eyes, Blurred vision

SECTION 12: Ecological information

12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

12.3 Bioaccumulative potential

Components:

Tafluprost:

Partition coefficient: n-

octanol/water

log Pow: 4.5

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.1 28.09.2024 564736-00020 Date of first issue: 15.03.2016

IMDG : Not regulated as a dangerous goodIATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.1 28.09.2024 564736-00020 Date of first issue: 15.03.2016

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not.

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone

layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation. H360D : May damage the unborn child.

H370 : Causes damage to organs if swallowed.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H413 : May cause long lasting harmful effects to aquatic life.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.1 28.09.2024 564736-00020 Date of first issue: 15.03.2016

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice: IARC - International Agency for Research on Cancer: IATA - International Air Transport Association: IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Tafluprost Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 564736-00020
 Date of first issue: 15.03.2016

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN